Drug: Ivermectin

What It Is

Ivermectin is an antiparasitic drug derived from avermectin, a compound made by a single strain of soil bacterium, Streptomyces avermitilis, isolated in Japan by Satoshi Omura and developed into a medicine by William Campbell. That work earned the two a share of the 2015 Nobel Prize in Physiology or Medicine. It sits on the World Health Organization Essential Medicines List and is one of the safest antiparasitics in wide use. It treats several parasitic diseases that once blinded and disabled millions, and it is given both to individuals and, in public-health campaigns, to whole communities at once.

The drug has two reputations that do not match. To tropical medicine it is a cheap once-a-year tablet that has driven river blindness toward elimination across much of Africa. To a wider public it became known during the pandemic either as a suppressed COVID cure or as a horse dewormer, and neither description is accurate.

How It Works

Anatomy

1The molecule

Ivermectin belongs to the avermectins, large ring-shaped molecules produced by the soil bacterium Streptomyces avermitilis. It was refined from that natural product into a medicine given as a tablet, and it is highly active against a range of worms and external parasites at very small doses. A single organism is the sole natural source of the whole avermectin family.

2The mechanism

Ivermectin binds glutamate-gated chloride channels, which sit in the nerve and muscle cells of invertebrates. Binding opens the channels, chloride ions rush in, the cells stop firing, and the parasite is paralyzed and dies. Mammals do not use these channels at the nerve-muscle junction, and a healthy blood-brain barrier keeps the drug out of the human central nervous system, which is why it is selectively toxic to the parasite and gentle on the person at approved doses.

3The approved forms

For people, ivermectin is an approved prescription medicine: oral tablets for parasitic infections such as strongyloidiasis and onchocerciasis, and topical formulations for head lice and for the skin condition rosacea. Highly concentrated veterinary pastes and injectables, made for large animals, are a different product entirely, and they were the source of the serious poisonings seen during the pandemic.

What It Treats

The antiparasitic record is strong and well documented. The uses below run roughly from the most firmly established to the more specific:

• River blindness (onchocerciasis). A systematic review of 238 treatment foci across 19 sub-Saharan African countries found that sustained mass administration drives the disease toward elimination of transmission, with the best results where treatment ran longest, reached at least 80% of people, and was given twice a year. The drug kills the microfilariae that cause the blindness and skin disease, so repeated rounds over many years are what carry a region to elimination.
• Lymphatic filariasis. A single dose of ivermectin combined with diethylcarbamazine and albendazole cleared the parasite from the blood in 96% of participants and held that clearance through two years. The single triple-drug dose was superior to the annual two-drug regimens, clearing in one treatment what the older approach needs repeated yearly rounds to reach.
• Strongyloidiasis. A randomized trial across Europe found a single dose cleared the intestinal worm in 86% of people, with extra doses adding nothing, which is why one dose is the standard.
• Scabies. A community trial cut prevalence by 94%.
• Head lice. A single ten-minute application of ivermectin lotion left most people lice-free two weeks later, far ahead of the placebo lotion.
• Rosacea. A topical ivermectin cream is an approved treatment for this common facial rash, linked to Demodex skin mites, where two twelve-week trials cleared or nearly cleared the skin in about four in ten people, roughly double the vehicle cream.

Across all of these, tolerability at approved doses was good, which is what made mass treatment of hundreds of millions of people possible.

The COVID Question

For most of its history ivermectin was known only to people who work on tropical disease. The pandemic changed that after a single laboratory study in 2020 reported that ivermectin suppressed SARS-CoV-2 in infected cells. That was a legitimate lead, and the clinical question grew from it. It also split into two inaccurate public stories at the same time: ivermectin as a suppressed miracle, and ivermectin as nothing more than a horse dewormer. The first ignored the trials; the second ignored that this is a Nobel-winning human medicine on the Essential Medicines List.

The evidence then accumulated in a clear order:

1. The starting signal was in vitro. Adding ivermectin to infected cells produced roughly a 5000-fold drop in SARS-CoV-2 over 48 hours, but only at a concentration many times higher than the blood or lung levels a person can reach at tolerable oral doses. That is a lead to test, not a treatment.
2. Some early clinical trials were positive, but several were small, and the most influential of them, by Elgazzar, was withdrawn from its preprint server over serious data-integrity problems.
3. The large preregistered trials then reported. TOGETHER, ACTIV-6, and PRINCIPLE, three randomized trials in outpatients, each found no meaningful benefit on recovery or hospitalization. PRINCIPLE, the largest at 8811 people, measured a small recovery difference that its own investigators had defined in advance as too small to matter, and it did not carry through to hospitalizations or deaths.
4. A Cochrane review that set aside the trials with the weakest methods and registration found little or no effect on death or quality of life for outpatients.

The large, preregistered, low-bias trials outweigh the laboratory signal and the small or withdrawn studies.

Ivermectin is one of the best antiparasitic drugs ever made, and for COVID the largest preregistered trials found no meaningful benefit. Both are true at once.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Infection And Antimicrobial

Ivermectin mass treatment across 238 foci in 19 African countries is driving river blindness toward eliminationStrong

In plain terms

Across hundreds of treated communities in Africa, giving ivermectin to whole populations year after year has pushed river blindness toward being wiped out, and the places that treated longest, most often, and reached the most people did best.

In detail

A systematic review and meta-analysis of 282 records from 238 distinct foci across 19 sub-Saharan African countries found that sustained mass drug administration of ivermectin drives onchocerciasis toward elimination of transmission. Ten or more years of treatment at 80% or higher coverage, 15 to 19 years of treatment, and twice-yearly dosing were each strongly associated with reaching or approaching elimination. Elimination of transmission was reported in 9% of records and being close to it in a further 30%. Ivermectin kills the microfilariae, not the long-lived adult worms, so repeated rounds over many years are needed and 61% of records still showed ongoing transmission. Elimination depends on sustained high coverage rather than the drug alone.

The study · 1

Mutono et al., elimination of transmission of onchocerciasis with long-term ivermectin mass drug administration in sub-Saharan Africa · Lancet Glob Health 2024;12(5):e771-e782

A single three-drug dose cleared lymphatic filariasis from the blood in 96% and held it clear through two yearsStrong

In plain terms

One dose of a three-drug combination cleared the filariasis parasite from the blood in almost everyone and kept it clear through two years, matching in a single treatment what the older two-drug regimen needs repeated annual rounds to achieve.

In detail

In a randomized trial in Papua New Guinea, a single dose of ivermectin plus diethylcarbamazine plus albendazole cleared Wuchereria bancrofti microfilariae from the blood in 96% of participants at both 12 and 24 months, against 32% at 12 months for a single dose of the standard two-drug regimen. At 24 months clearance was 56% after a single dose of the two-drug regimen and 75% after two annual doses of it, so the single triple-drug dose was superior to both, matching in one treatment what the two-drug regimen needs repeated annual rounds to achieve. Moderate short-term reactions were more common with the three-drug dose than the two-drug regimen, 27% against 5%, with no serious adverse events. This was 182 adults in one setting.

The study · 1

King et al., a trial of a triple-drug treatment for lymphatic filariasis · N Engl J Med 2018;379(19):1801-1810

One dose of ivermectin cleared strongyloidiasis in 86%, and four doses added nothingStrong

In plain terms

For this intestinal worm, one dose of ivermectin cleared the infection in most people, and taking four doses instead of one added nothing except more side effects.

In detail

In a multicenter randomized trial across Italy, Spain and the UK, a single 200 microgram per kilogram dose of ivermectin cleared Strongyloides stercoralis infection at 12 months in 86% of participants, statistically indistinguishable from four doses at 85%. The trial was stopped early for futility because extra doses added no benefit and were tolerated less well, establishing the single dose as the standard. This was measured in a non-endemic population with mostly imported, non-disseminated infection. Severe disseminated strongyloidiasis and hyperinfection in people who are immunocompromised are managed differently. The trial was open-label.

The study · 1

Buonfrate et al., multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4) · Lancet Infect Dis 2019;19(11):1181-1190

One community round of ivermectin cut scabies from 32.1% to 1.9%, a 94% reductionStrong

In plain terms

Giving ivermectin to an entire community once cut scabies from affecting about one in three people to about one in fifty within a year, and roughly halved the skin infections that scabies causes.

In detail

In a Fijian trial that assigned island communities to different strategies, one round of mass ivermectin cut scabies prevalence from 32.1% to 1.9% at 12 months, a 94% relative reduction, the largest of any group, and cut impetigo, the skin infection scabies drives, by 67%. This was three island communities, so few independent units sit behind the summary figure. Mild adverse events were more frequent with ivermectin than permethrin, 15.6% against 6.8%, and it is a single trial in one region.

The study · 1

Romani et al., mass drug administration for scabies control in a population with endemic disease · N Engl J Med 2015;373(24):2305-2313

A single 10-minute ivermectin lotion left 94.9% louse-free the next day and 73.8% at two weeksStrong

In plain terms

A single ten-minute application of ivermectin lotion cleared head lice in most people and kept them clear two weeks later, far better than the placebo lotion, without the tedious nit-combing.

In detail

In two randomized, double-blind trials, a single 10-minute application of 0.5% ivermectin lotion, with no nit combing, left 94.9% of patients louse-free the day after treatment and 73.8% still louse-free at day 15, against 17.6% for the vehicle control. Adverse events were similar in both groups. The trials were funded by the product maker, they tested a specific topical formulation rather than tablets, and the day-15 figure shows clearance is high but not complete.

The study · 1

Pariser et al., topical 0.5% ivermectin lotion for treatment of head lice · N Engl J Med 2012;367(18):1687-1693

Skin And Hair

Ivermectin 1% cream cleared or nearly cleared papulopustular rosacea in 38.4% and 40.1% of people over 12 weeksStrong

In plain terms

For the common facial rash rosacea, a daily ivermectin cream cleared or nearly cleared the skin in about four in ten people over twelve weeks, roughly double the vehicle cream, and cut the inflamed spots by about three quarters.

In detail

In two identically designed, randomized, double-blind, vehicle-controlled pivotal trials, once-daily ivermectin 1% cream for 12 weeks achieved treatment success, rated clear or almost clear, in 38.4% and 40.1% of people with moderate-to-severe papulopustular rosacea, against 11.6% and 18.8% on the vehicle cream. Inflammatory lesion counts fell 76.0% and 75.0% from baseline, against 50.0% for the vehicle. These were manufacturer-sponsored trials of a topical cream for papulopustular rosacea, a use separate from the oral antiparasitic role. Rosacea is linked to Demodex skin mites, which the cream is thought to target, and treatment success here means clear or almost clear, not a cure.

Who this may not transfer to:Both trials enrolled adults with moderate-to-severe papulopustular rosacea; the result applies to that facial skin condition, not to the oral antiparasitic uses.

The study · 1

Stein et al., efficacy and safety of ivermectin 1% cream in papulopustular rosacea (two pivotal studies) · J Drugs Dermatol 2014;13(3):316-323

Respiratory Infection

The three largest home-treatment trials, PRINCIPLE at 8811, found no meaningful COVID recovery or hospitalization benefitStrong · no effect

In plain terms

The three biggest, best-run trials in people with COVID at home came to the same place: ivermectin did not meaningfully speed recovery and did not cut the chance of ending up in hospital.

In detail

The three largest randomized trials in outpatients agree. TOGETHER found a relative risk of 0.90 (credible interval 0.70 to 1.16) for hospitalization or extended emergency observation. ACTIV-6 found a recovery hazard ratio of 1.07 (0.96 to 1.17), a median 12 versus 13 days, with 10 versus 9 hospitalizations or deaths. PRINCIPLE, the largest at 8811 participants, found recovery a median 2.06 days faster but well below its own threshold for a meaningful effect, with no difference in hospitalizations, deaths, or recovery at six months. These trials studied mild-to-moderate outpatient COVID, largely in vaccinated populations. PRINCIPLE did detect a small recovery-time difference, but one its investigators had defined in advance as too small to be clinically meaningful, and it did not carry through to hospitalization or long-term recovery.

The studies · 3

Reis et al., effect of early treatment with ivermectin among patients with Covid-19 (TOGETHER) · N Engl J Med 2022;386(18):1721-1731

Naggie et al., effect of ivermectin vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19 (ACTIV-6) · JAMA 2022;328(16):1595-1603

Hayward et al., ivermectin for COVID-19 in adults in the community (PRINCIPLE) · J Infect 2024;88(4):106130

Pooling only the better-run COVID trials showed no effect on death, risk ratio 0.77Strong · no effect

In plain terms

When researchers pooled only the COVID trials that met basic quality and registration standards, ivermectin showed no clear effect on dying or on quality of life. Restricting to the better-run studies is what changed the earlier, more favorable picture.

In detail

A Cochrane review that excluded 7 of 14 earlier trials for failing prospective registration or integrity checks pooled the remaining evidence. For outpatients it found moderate-certainty evidence of little or no effect on all-cause mortality (risk ratio 0.77, 95% confidence interval 0.47 to 1.25, 6 trials, 2860 participants) and high-certainty evidence of no effect on quality of life. The picture held once the trials with the weakest methods were set aside. Evidence for inpatients with severe disease remained very low certainty, so no strong claim can be made there. The strength of this review is what it excluded: seven trials that were not prospectively registered or were not randomized, including work later withdrawn for data problems.

The study · 1

Popp et al., ivermectin for preventing and treating COVID-19 · Cochrane Database Syst Rev 2022;6:CD015017

How it works

Ivermectin paralyzes parasites by opening a nerve channel our own nerves do not useModerate · mixed

In plain terms

Ivermectin locks onto a channel that parasite nerves and muscles rely on but ours do not, which paralyzes the parasite. Our nervous system is shielded from it, which is why the same drug that kills the worm is gentle on the person at normal doses.

In detail

Ivermectin binds glutamate-gated chloride channels found in the nerve and muscle cells of invertebrates. Binding opens the channels, chloride floods in, the cells are hyperpolarized, and the parasite is paralyzed and dies. Mammals do not use these channels at the nerve-muscle junction, and an intact blood-brain barrier keeps the drug out of the mammalian central nervous system, which is the basis of its wide safety margin at approved doses. The selectivity depends on the blood-brain barrier holding the drug out of the brain. The same channel family exists in the mammalian central nervous system, so very high doses, or a compromised barrier, can produce neurological effects, which is the mechanism behind overdose toxicity.

The study · 1

Laing, Gillan and Devaney, ivermectin, old drug new tricks · Trends Parasitol 2017;33(6):463-472

Ivermectin cut SARS-CoV-2 in cell culture 5000-fold, but only at a dose people cannot safely reachPreliminary · mixed

In plain terms

In a dish of cells, ivermectin knocked the virus down sharply. The catch was that it took a dose far higher than a person could safely reach in the body, so the dish result was a lead to check, not a treatment.

In detail

An early laboratory study reported that adding ivermectin to infected monkey kidney cells produced roughly a 5000-fold reduction in SARS-CoV-2 RNA at 48 hours. The concentration required was many times higher than the blood and lung levels reachable in a person at approved or tolerable oral doses, which is the gap the later clinical trials had to test. A cell-culture result at a concentration that cannot be achieved safely in people does not establish a clinical effect. This finding launched the clinical question; it did not answer it. The large trials that followed found no meaningful benefit.

The study · 1

Caly et al., the FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro · Antiviral Res 2020;178:104787

Go Deeper

• How industry shapes science: how to read past funding, framing, and buried data, the method the ivermectin COVID story needs.
• Expectancy and belief: how conviction, the placebo response, and a compelling narrative can make a treatment feel effective ahead of the evidence.
• Ozone therapy: another treatment promoted hard during the pandemic, and how to weigh a contested therapy against the trials.
• Methylene blue: an old, cheap compound with established uses and a wave of modern claims that run ahead of the human evidence.

The Chinese Medicine View

Ivermectin is a product of modern microbiology and has no entry in the classical Chinese pharmacopoeia. No historical text assigns it a channel, a temperature, or a flavor, and there is no traditional preparation that resembles it. What the tradition does have is a long-standing category for the problem the drug treats, and that is a lens, not evidence.

Chinese medicine treats parasites plainly. Expelling worms and parasites is a named therapeutic category, and the tradition kept a working group of antiparasitic herbs for it, all used to expel intestinal worms:

• Bing Lang, the areca nut
• Shi Jun Zi, the fruit of Quisqualis
• Ku Lian Pi, the bark of the chinaberry tree

The underlying idea is that a parasite is something that does not belong in the body and consumes its resources, so the treatment is to dispel what does not belong and then rebuild what it depleted. A modern antiparasitic does the removing: it clears the organism, and the body recovers once the parasite is gone.

This sets a modern drug beside a much older framework, and it is not a claim that Chinese medicine discovered or endorses ivermectin. The old texts describe the problem of parasites and an herbal approach to it; the evidence for ivermectin itself rests entirely on the trials.

Cautions For This Practice

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

At the approved 200 microgram-per-kilogram dose, side effects were few and mild across 15 trials

A Cochrane review of 15 scabies trials with 1896 participants found that adverse events with standard-dose oral ivermectin, 200 micrograms per kilogram, were few and mild and broadly comparable to topical permethrin, with no withdrawals due to adverse events reported in the ivermectin arms. This tolerability at approved doses underlies decades of mass-treatment use in hundreds of millions of people. Adverse-event reporting in the underlying trials was often incomplete. This tolerability applies to standard antiparasitic dosing, not to the high or repeated off-label doses that drove the poisoning cases seen during the pandemic.Rosumeck, Nast and Dressler, ivermectin and permethrin for treating scabies (Cochrane review)

High-dose and veterinary ivermectin poisoned 37 people in one case series, and one died

A poison-center case series of 37 people who took ivermectin for COVID-19 found that those using veterinary formulations took larger doses and had higher rates of altered mental status than those using human tablets. Twenty-one were hospitalized, thirteen treated in an emergency department, and one died; neurotoxicity appeared in 30. The pattern tracked dose and formulation, not the drug at its approved dose. This is a single poison-center case series, so it describes who was harmed rather than a rate across all users. The cases concentrated in older adults taking large single doses or daily doses for weeks, well outside approved antiparasitic use.Hoang, characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19

Among 17,877 treated in a Loa loa endemic area, severe reactions rose sharply above 8000 microfilariae per milliliter

Among 17,877 people treated during an onchocerciasis campaign in a Loa loa endemic area of Cameroon, the risk of marked or serious reactions rose sharply with pretreatment Loa loa load. Serious reactions became far more likely above 8000 microfilariae per milliliter, and two people developed a coma with Loa loa parasites detected in the cerebrospinal fluid. Twenty had serious functional impairment lasting over a week. This risk is specific to areas where loiasis is endemic and to heavy co-infection, which is why mass-treatment programs screen Loa loa load beforehand. It does not describe the drug used for ordinary indications outside those regions.Gardon et al., serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection

Veterinary and concentrated formulations

The serious poisonings during the pandemic came from people taking veterinary pastes and injectables made for horses and cattle, which are far more concentrated than any human medicine. The harm tracked the overdose and the formulation, not ivermectin at its approved dose. Products made for large animals are not interchangeable with a human prescription, and the dose they deliver can be many times too high.

Dose and prescription

Ivermectin for people is a prescription medicine, dosed by body weight and by the specific parasite being treated, and decided by a clinician. Pushing the dose far above the approved range narrows the safety margin, because enough drug can then reach the central nervous system, which is the mechanism behind the neurological symptoms seen in overdose.

Drug interactions

Ivermectin can interact with other medicines, and combining it with drugs that raise its levels or that also act on the central nervous system can increase side effects. Anyone taking regular medication should have the combination checked before use.

Loa loa in endemic regions

In parts of Central and West Africa where the Loa loa worm is common, people carrying a very heavy Loa loa load can have severe reactions to ivermectin, including, rarely, a dangerous brain reaction. This is why mass-treatment programs screen for Loa loa load before dosing in those regions. It is a co-infection interaction specific to endemic areas, not a general property of the drug.

Pregnancy

Ivermectin is generally not given during pregnancy outside specific supervised circumstances, because the safety data in pregnancy are limited. This is a decision for a clinician who knows the individual situation, weighing the parasite being treated against what is known.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Is ivermectin a good medicine?

Yes. It is one of the most valuable antiparasitic drugs ever developed, effective against river blindness, lymphatic filariasis, strongyloidiasis, scabies, and head lice, and very safe at approved doses. Its discovery earned a share of the 2015 Nobel Prize in Medicine, it is on the World Health Organization Essential Medicines List, and hundreds of millions of people have received it in mass-treatment campaigns that have driven some diseases toward elimination. The COVID controversy is a separate chapter and takes nothing away from that record.

Does ivermectin work for COVID?

The best evidence says it does not meaningfully help. An early laboratory study found activity against the virus in a dish, but only at a concentration far higher than a person can safely reach. The three largest randomized outpatient trials, TOGETHER, ACTIV-6, and PRINCIPLE, found no meaningful benefit on recovery or hospitalization, and a Cochrane review focused on the best-conducted trials found little or no effect on death or quality of life. A COVID benefit is not established.

Why did people call it horse dewormer?

Because some people took concentrated ivermectin made for horses and cattle, which is far stronger than any human dose, to prevent or treat COVID. That framing was accurate about the misuse of a veterinary product and inaccurate about the drug itself, a Nobel-winning human medicine used worldwide. Both the suppressed-miracle story and the horse-dewormer story departed from what the evidence shows.

Was ivermectin research suppressed?

The simpler explanation fits the facts. Early enthusiasm rested on small trials and on at least one study later withdrawn for data problems, and as the large, rigorous, preregistered trials reported, they found no meaningful benefit. That is the ordinary path of a promising early signal that does not hold up under better testing. Weighting large, low-bias trials above early laboratory results and small studies is how sound conclusions are reached.

Is ivermectin safe?

At approved antiparasitic doses it is very safe, which is why it can be given to hundreds of millions of people in mass campaigns, with side effects that are usually few and mild. The danger appears with large overdoses, especially of concentrated veterinary products, which can reach the brain and cause neurological symptoms. There is also a specific risk in regions where the Loa loa worm is endemic, where heavy co-infection can trigger severe reactions, which is why those programs screen first.